Organovo (ONVO) Raised to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Organovo (NASDAQ:ONVO) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, Zacks.com reports. The brokerage currently has $0.50 target price on the medical research company’s stock.
According to Zacks, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. “
Organovo stock opened at $0.55 on Thursday. Organovo has a twelve month low of $0.37 and a twelve month high of $1.97. The company has a market cap of $96.25 million, a PE ratio of -1.73 and a beta of 1.79.
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Article: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.